Clinical Trial Update: Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of venetoclax and azacitidine in AML patients selected by ex vivo drug sensitivity screening has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: Helsinki University Central Hospital | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED